Recent Price Movement and Market Context
On 4 December 2025, Shree Ganesh Remedies’ stock touched an intraday low of Rs.423, representing a 7.22% drop from its previous levels. This new low comes after two consecutive sessions of decline, during which the stock recorded a cumulative return of -4.39%. Despite an intraday high of Rs.466.95, the share price closed significantly lower, underperforming its sector by 2.16% on the day.
The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward pressure. This contrasts with the broader market, where the Sensex recovered from an initial negative opening to close 0.12% higher at 85,210.32, remaining just 1.11% shy of its 52-week high of 86,159.02. The Sensex’s positive momentum was supported by mega-cap stocks and bullish moving averages, highlighting a divergence between Shree Ganesh Remedies and the overall market trend.
Performance Over the Past Year
Over the last twelve months, Shree Ganesh Remedies has recorded a return of -39.14%, significantly lagging behind the Sensex, which posted a gain of 5.16% during the same period. The stock’s 52-week high was Rs.950, indicating a substantial reduction in value from its peak. This underperformance extends to the broader BSE500 index, which generated a modest 2.33% return over the year, further emphasising the stock’s relative weakness.
Built for the long haul! Consecutive quarters of strong growth landed this Small Cap from Chemicals on our Reliable Performers list. Sustainable gains are clearly ahead!
- - Long-term growth stock
- - Multi-quarter performance
- - Sustainable gains ahead
Financial Results and Profitability Trends
Shree Ganesh Remedies has reported negative results for three consecutive quarters, with key profitability metrics showing contraction. The Profit Before Tax (PBT) for the latest quarter stood at Rs.6.02 crore, reflecting a decline of 28.76%. Similarly, the Profit After Tax (PAT) was Rs.4.96 crore, down by 22.6% compared to previous periods. These figures indicate a reduction in earnings, contributing to the subdued market sentiment surrounding the stock.
The company’s Return on Capital Employed (ROCE) for the half-year period is recorded at 16.18%, which is among the lower levels observed recently. Return on Equity (ROE) stands at 13.3%, suggesting a moderate level of profitability relative to shareholder equity. The Price to Book Value ratio is 3.8, indicating that the stock is trading at a valuation discount compared to its peers’ historical averages.
Debt and Valuation Metrics
Despite the challenges in earnings, Shree Ganesh Remedies maintains a relatively low Debt to EBITDA ratio of 0.47 times, signalling a strong capacity to service its debt obligations. This financial metric suggests that the company’s leverage is manageable, which may provide some stability amid earnings fluctuations.
From a valuation standpoint, the stock’s current price level reflects a discount relative to its sector peers, which may be attributed to the recent earnings contraction and price decline. Domestic mutual funds hold no stake in the company, which may reflect a cautious stance given the recent financial performance and market dynamics.
Sector and Market Comparison
Operating within the Pharmaceuticals & Biotechnology sector, Shree Ganesh Remedies has underperformed relative to its industry peers and the broader market indices. While the sector has seen varied performance, the company’s stock has not aligned with the positive trends observed in larger indices such as the Sensex, which continues to trade above its 50-day moving average with a bullish configuration.
The divergence between Shree Ganesh Remedies and the broader market highlights the specific challenges faced by the company, as well as the differing investor sentiment towards micro-cap stocks within the pharmaceutical space.
Considering Shree Ganesh Remedies ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Summary of Key Concerns
The stock’s fall to Rs.423 marks a significant milestone in its recent price trajectory, reflecting ongoing pressures from declining profitability and subdued market interest. The absence of domestic mutual fund holdings may indicate limited institutional engagement, while the stock’s trading below all major moving averages underscores the prevailing bearish momentum.
While the company’s debt servicing ability remains sound, the contraction in earnings and returns has weighed on valuation and investor confidence. The stock’s performance over the past year, with a near 40% reduction in price and over 28% fall in profits, highlights the challenges faced by Shree Ganesh Remedies in maintaining growth and market positioning.
Market Environment and Broader Implications
In contrast to Shree Ganesh Remedies’ performance, the broader market indices have shown resilience, with the Sensex trading near its 52-week high and supported by mega-cap stocks. This divergence emphasises the selective nature of market gains and the varying fortunes of companies within the Pharmaceuticals & Biotechnology sector.
Investors and market participants may continue to monitor the stock’s price action and financial disclosures closely, given the recent developments and the company’s position within the sector.
Limited Time Only! Upgrade now and get 1 Year of Stock of the week worth Rs. 14,999 for FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
